Trial Profile

A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; MOMA 341 (Primary)
Indications Colorectal cancer; Endometrial cancer; Gastric cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors MOMA Therapeutics

Most Recent Events

17 Jul 2025 According to MOMA Therapeutics media release, the first patient has been dosed in its Phase 1 clinical trial, and the company anticipates an initial readout of monotherapy data in mid-2026.
17 Jul 2025 Status changed from not yet recruiting to recruiting, according to a MOMA Therapeutics media release.
23 May 2025 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com